<DOC>
	<DOCNO>NCT01029795</DOCNO>
	<brief_summary>The purpose study help answer follow research question ( ) : - To test take LY2599506 12 week control blood sugar well take glyburide 12 week . - To evaluate safety LY2599506 participant diabetes . - To determine LY2599506 ability control blood sugar participant diabetes . - To determine much LY2599506 give participant . - To determine LY2599506 effect participant 's weight . The study design consist 4 study period : screening period , 4-week dose adjustment period , 8-week treatment period , 4-week follow period .</brief_summary>
	<brief_title>A Study LY2599506 ( Oral Agent Medication : Glucokinase Activator 1 ) Type 2 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Glyburide</mesh_term>
	<criteria>Have type 2 diabetes mellitus prior enter trial Are currently treat diet exercise therapy consistent local standard medical care Treated : Diet exercise alone ; Diet exercise combination stable dose metformin least 3 month prior enter trial ; Diet exercise combination stable dose sulfonylurea least 3 month prior enter trial ; Diet exercise combination stable dos metformin sulfonylurea least 3 month prior enter trial diabetes least 6 year . Have HbA1c value 7 % 10 % Are woman childbearing potential due surgical sterilization ( hysterectomy bilateral oophorectomy tubal ligation ) menopause . Male patient advise use reliable method birth control study 3 month last dose study medication partner childbearing potential . Use insulin antidiabetic agent metformin sulfonylurea 3 month prior enter trial . Have gastrointestinal disease significantly impact gastric empty motility ( example , severe gastroparesis pyloric stenosis ) , opinion Investigator , undergone gastric bypass gastric banding surgery . Have 1 episode severe hypoglycemia within 6 month prior entry study , currently diagnose hypoglycemia unawareness Have 2 emergency room visit hospitalization due poor glucose control past 6 month . Have cardiac autonomic neuropathy ( example , rest tachycardia orthostatic hypotension ) , base clinical sign , symptom , appropriate diagnostic testing . Have cardiac disease functional status New York Heart Association Class II , III , IV history myocardial infarction , unstable angina , decompensated congestive heart failure past 6 month . Have poorly control hypertension ( , mean systolic blood pressure &gt; 160 mm Hg mean diastolic blood pressure &gt; 100 mm Hg ) history malignant hypertension , evidence renal artery stenosis , and/or evidence labile blood pressure include symptomatic postural hypotension . Doses antihypertensive medication must stable 30 day randomization . Have feed fast state hypertriglyceridemia ( define &gt; 6.8 millimoles per liter [ mmol/L ] , 600 milligram per deciliter [ mg/dL ] ) screening . If take lipidlowering agent , dos medication must stable 30 day prior randomization . Have obvious clinical sign symptom liver disease , acute chronic hepatitis , repeat alanine transaminase ( ALT ) level &gt; 2.5 time upper limit reference range screening . Have evidence significant active , uncontrolled endocrine autoimmune abnormality , judge Investigator screen . Have active untreated malignancy remission clinically significant malignancy ( basal squamous cell skin cancer , situ carcinoma cervix , situ prostate cancer ) less 5 year . Have history seizure disorder .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2011</verification_date>
</DOC>